[Yu Jin-hee, Edaily Reporter] As capital continued to flow into the semiconductor sector in the domestic stock market, the biotech and medical technology sectors also saw steady valuation gains, particularly among companies backed by solid earnings and clear growth momentum.

Amid generally positive market sentiment, investor interest selectively focused on promising companies that had proven their value through tangible performance and strong regulatory support, rather than on those driven by mere speculative expectations. On June 12, three companies—JLK, DT&C RO, and Angel Robotics—posted sharp double-digit gains, securing spots on the daily list of top gainers and leading qualitative growth across the biotech sector.

JLK Driven by Strong Earnings Expectations, Leading the Sector’s Top Gainers

According to KG Zeroin’s MP DOCTOR, medical artificial intelligence (AI) specialist JLK closed at 5,210 won, soaring 21.45% from the previous session to establish itself as the dominant driver in the sector. Full-service contract research organization (CRO) DT&CRO also ended the day up 15.09% at 2,670 won, while wearable robotics pioneer Angel Robotics concluded trading at 24,750 won, a 12.76% jump.

Unlike other tech stocks that saw temporary spikes driven by short-term trends, these three companies saw their share prices rise on the back of distinct, significant catalysts—ranging from major regulatory overhauls targeting the U.S. market and structural infrastructure turnarounds to securing monumental government-led national projects. Consequently, their long-term market outlook remains highly favorable.

The primary external catalyst driving JLK’s surge is sweeping regulatory easing in the United States, the world’s largest healthcare market. The U.S. Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) have officially launched the “RAPID” (Regulatory Alignment for Predictable and Immediate Device) program, a new track designed to dramatically shorten the timeline for local insurance coverage of innovative medical devices.

Previously, even after clearing the stringent FDA approval hurdle, medical device firms faced a massive commercialization bottleneck, often taking years to secure insurance reimbursement codes before generating actual hospital sales. Under the RAPID framework, however, a parallel review system has been established, allowing the FDA approval process and the CMS insurance coverage evaluation to run concurrently.

As a result, the National Coverage Determination (NCD) is announced on the very day of FDA approval, paving the way for companies to generate commercial revenue across U.S. hospitals in as little as two months.

Having already secured FDA clearances for seven of its stroke AI pipelines—led by its flagship large vessel occlusion (LVO) auto-detection solution, 'JLK-LVO'—and actively pursuing local reimbursement pathways, JLK has been identified as the most direct beneficiary of this policy shift.

Commercialization breakthroughs on the domestic front further fueled the stock’s momentum. JLK recently announced that 'JLK-CTP,' its proprietary AI solution for brain CT perfusion image analysis, has been designated for the New Medical Technology Assessment Deferral program in South Korea.

This deferral allows the solution to immediately enter clinical settings under a non-reimbursable (out-of-pocket) model completely free from price ceilings. Given the precedent set by Vuno’s 'DeepCARS,' which experienced explosive growth and generated tens of billions of won in standalone revenue following a similar deferral designation, market experts anticipate a sharp, near-term jump in JLK’s financial performance.

Furthermore, JLK is accelerating its business-to-business (B2B) expansion by leveraging 'JOOMED,' its multimodal Large Language Model (LLM) platform specialized in medical imaging. The company aims to embed its AI solutions directly into the systems of global medical imaging hardware manufacturers, a strategy projected to simultaneously expand short-term sales volume and drive long-term profitability.

"With JLK-CTP demonstrations currently underway across a multitude of hospitals, we are anticipating an imminent increase in revenue," a JLK representative stated. "We will continue to diversify our business models to optimize both top-line growth and structural profitability."

Moving Out of the Red Toward Operating Profits: DT&CRO Signals Structural Turnaround

The upward trajectory of DT&CRO’s stock price reflects the market’s re-evaluation of its intrinsic financial metrics, marked by robust restructuring and earnings normalization. According to independent research and market analysis, DT&CRO has successfully broken its streak of operating losses and has positioned itself at the forefront of a structural turnaround toward profitability.

The company’s operating loss, which stood at 11.3 billion won in 2024, was nearly halved to 5.7 billion won in 2025. Concurrently, its annual revenue surged 32.7% year-on-year to 477 billion won, signaling that its overall cost-and-profit structure has firmly stabilized on an upward trend—a trend widely expected to persist through this year.

The primary driver behind this bottom-line rebound is the operational normalization of its Efficacy and Safety Evaluation Centers. The utilization rate of the Safety Evaluation Center, which hovered at a sluggish 53.7% in 2024, shot up to 74.9% in 2025, pushing the company into a highly profitable zone where fixed costs are efficiently absorbed by rising revenues. With a robust order backlog currently standing at 518 billion won, the company has earned high marks for earnings predictability and mid-to-long-term stability.

Breaking away from the traditional boundaries of a standard clinical CRO, DT&CRO is actively promoting its comprehensive “One CRO, All Solutions” framework, which seamlessly integrates efficacy testing, GLP toxicology studies, bioanalysis, Phase 1–4 clinical trials, and regulatory consulting under a single umbrella.

In particular, its newly opened Pharmacokinetics (PK) and Pharmacodynamics (PD) Center, established through a 23.8 billion won capital investment, is projected to evolve into a high-margin data hub.

Rather than acting as a mere testing service provider, the center offers strategic consulting for clinical dose escalation and overall drug development roadmaps, meaning that as utilization increases, the margin-expansion effect will be maximized. Concurrently, its strategic alliance with U.S.-based Radyus Research for global FDA consulting is yielding substantial results, serving as a vital international sales pipeline that channels initial pre-IND consulting clients into subsequent domestic GLP toxicology and main clinical trial contracts.

"Based on our integrated service pipeline spanning efficacy, toxicology, bioanalysis, PK/PD, and full-scale clinical trials, we are delivering optimized end-to-end solutions to our clients," a DT&CRO executive emphasized. "We intend to consistently elevate our distinctive corporate value on the foundation of this unified platform."

Thought-Driven, Bidirectional Brain-Robot Synchronization: Angel Robotics Secures Landmark National Project

Angel Robotics saw intense institutional and foreign buying pressure following an official announcement that it had been selected as the sole lead operating institution for a massive, government-funded national R&D project. The initiative, orchestrated by the Ministry of Trade, Industry and Energy (MOTIE), is a state-backed project titled, 'Development and Commercialization of a Brain-to-Robot Full-Stack System Capable of Motor-Sensory Synchronization.'

Spanning approximately six years and nine months through December 2032, this high-stakes project has a total budget of 23.547 billion won. Of this amount, the government-endorsed R&D funding directly allocated to Angel Robotics totals 6.99 billion won—a substantial sum equivalent to 21.4% of the company’s total equity.

The project’s technical credibility is further bolstered by the strategic participation of ten elite domestic research institutions, including the Korea Advanced Institute of Science and Technology (KAIST) and the Seoul National University R&D Foundation.

The core objective of this project is to implant high-resolution neuro-electrodes into the cerebral cortex of patients suffering from quadriplegia or total paralysis. The moment the user conceptualizes a physical movement—such as taking a step or reaching out an arm—an AI engine interprets the brain signals in real time to actuate a wearable robot.

Crucially, the scope of this project goes far beyond conventional, one-way thought-to-movement control. It aims to achieve true “bidirectional motor-sensory synchronization,” a breakthrough technology where sensory inputs detected by the robot—such as ground pressure, physical contact, and spatial positioning—are transmitted back into the user’s neural pathways, allowing the patient to consciously perceive the robot’s environment.

Angel Robotics has already established its world-class robotics architecture through its 'WalkON Suit' series, designed for individuals with paraplegia. By securing both the foundational intellectual property for this next-generation mobility system and a leading role in shaping global regulatory guidelines, Angel Robotics has successfully created a vital springboard to elevate its mid-to-long-term corporate valuation and technology premium.

"Securing this national project positions us to simultaneously capture foundational source technologies for the future mobility and advanced medical device markets while actively contributing to global regulatory frameworks," a representative from Angel Robotics stated. "This milestone will serve as a monumental turning point, elevating our mid-to-long-term corporate value and technological premium to a whole new level."